Analyst Price Targets — CLYM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 11, 2026 4:20 pm | Julian Harrison | BTIG | $20.00 | $11.17 | TheFly | Climb Bio price target raised to $20 from $19 at BTIG |
| June 8, 2026 11:13 am | — | Guggenheim | $35.00 | $10.55 | TheFly | Climb Bio initiated with a Buy at Guggenheim |
| May 12, 2026 10:13 am | Raghuram Selvaraju | H.C. Wainwright | $20.00 | $11.12 | TheFly | Climb Bio price target raised to $20 from $15 at H.C. Wainwright |
| May 8, 2026 1:39 pm | — | Wedbush | $17.00 | $12.06 | TheFly | Climb Bio price target raised to $17 from $15 at Wedbush |
| May 6, 2026 10:44 am | — | Robert W. Baird | $21.00 | $11.45 | TheFly | Climb Bio price target raised to $21 from $12 at Baird |
| May 5, 2026 8:02 am | — | Chardan Capital | $22.00 | $9.69 | TheFly | Climb Bio initiated with a Buy at Chardan |
| April 15, 2026 8:47 am | Joseph Catanzaro | Mizuho Securities | $18.00 | $8.85 | TheFly | Climb Bio initiated with an Outperform at Mizuho |
| March 17, 2026 8:06 pm | Danielle Brill | Truist Financial | $17.00 | $7.12 | StreetInsider | Truist Securities Starts Climb Bio (CLYM) at Buy |
| March 10, 2026 8:06 pm | Christopher Raymond | Raymond James | $25.00 | $7.33 | StreetInsider | Raymond James Starts Climb Bio (CLYM) at Strong Buy |
| December 18, 2025 11:06 am | Raghuram Selvaraju | H.C. Wainwright | $11.00 | $4.25 | TheFly | Climb Bio price target raised to $11 from $9 at H.C. Wainwright |
Latest News for CLYM
Climb Bio Inc. (NASDAQ:CLYM) on Thursday shared initial data from its ongoing Phase 1b portion of its Phase 1b/2a study of budoprutug for primary immune thrombocytopenia (ITP), an autoimmune disorder where the immune system mistakenly attacks and destroys platelets.
Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high dose cohort, with additional data anticipated by year-end 2026 WELLESLEY HILLS, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company…
Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer
WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced upcoming presentations for its CLYM116 and budoprutug programs at the European Renal Association Congress 2026, which will be held in Glasgow, Scotland June 3-6, 2026.
Climb Bio NASDAQ: CLYM outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright's BioConnect Conference, with management emphasizing two biologic drug programs aimed at immune-mediated diseases, including nephrology and hematology indications.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLYM.
U.S. House Trading
No House trades found for CLYM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.